טוען...
Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
BACKGROUND: Alectinib is a highly selective tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK) and provided a significantly prolonged progression-free survival compared with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) harboring rearrangements of the ALK gene....
שמור ב:
| הוצא לאור ב: | Surg Case Rep |
|---|---|
| Main Authors: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Springer Berlin Heidelberg
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5845085/ https://ncbi.nlm.nih.gov/pubmed/29524063 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40792-018-0430-7 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|